Corvus Pharmaceuticals Inc (NAS:CRVS)
$ 1.83 0.05 (2.81%) Market Cap: 114.47 Mil Enterprise Value: 90.25 Mil PE Ratio: 0 PB Ratio: 2.69 GF Score: 42/100

Corvus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 01:30PM GMT
Release Date Price: $3.5 (+1.45%)
Richard Miller
Corvus Pharmaceuticals, Inc. - President, CEO

I'm not the analyst for Jefferies, I'm Richard Miller, I'm the CEO of Corvus. Really appreciate you all coming out to listen to this presentation. I have a lot to cover, so I think I'm going to jump right in. So let me have the next slide, I guess my control this.

What I'd like to do today is talk to you about three products that we have in the clinic, an ITK inhibitor, small molecule, A2A receptor antagonist, and an anti-CD73 antibody. I'm going to spend majority of the time, the bulk of the time talking about a drug we're pretty excited about. It's called an ITK inhibitor, I'll tell you all about that in a little bit.

This drug again, is a small molecule. Orally administered, is now, in a Phase-1b trial for relapsed T-cell lymphomas. We'll be reporting updated data on that in a couple of weeks at the Lugano meeting in Switzerland, International Conference on Malignant Lymphoma.

We plan to have additional data throughout the rest of the year. We are planning to meet with the FDA in late summer to discuss a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot